Introduction
============

The role of bacteria in the pathogenesis of airway inflammation and symptoms in stable COPD remains unclear. Potentially pathogenic microorganisms (PPMs) have been identified at stable state in bronchoalveolar lavage fluid[@b1-copd-10-1075],[@b2-copd-10-1075] and sputum.[@b3-copd-10-1075] The most commonly identified species are *Haemophilus influenzae* and *Moraxella catarrhalis*.[@b1-copd-10-1075],[@b2-copd-10-1075] Although often assumed to reflect colonization, previous work has shown that a single positive sputum culture for a PPM is associated with increased neutrophilic airway inflammation,[@b4-copd-10-1075],[@b5-copd-10-1075] worsened health status,[@b6-copd-10-1075] increased exacerbations,[@b7-copd-10-1075] and an increased risk of bacteria-associated exacerbations.[@b8-copd-10-1075] Moreover, antibiotic therapy in patients with stable COPD is associated with a reduction in sputum neutrophil counts in those with elevated bacterial loads.[@b9-copd-10-1075] These findings suggest that PPMs contribute directly to neutrophilic airway inflammation in patients with stable COPD.

More recently, quantitative real-time polymerase chain reaction (qPCR) has been used to detect respiratory PPMs, with the potential advantage of allowing rapid quantification of bacteria. How this measure compares with culture-dependent methods and whether it relates to airway inflammation and clinically important outcomes are largely unknown. We tested the hypothesis that the presence of PPMs in sputum measured by qPCR in subjects with stable COPD is a more sensitive measure of bacteria-associated neutrophilic airway inflammation by assessing the cross-sectional and longitudinal relationship between bacterial load, sputum neutrophil count, and clinical outcomes.

Methods
=======

Data was collected from a prospective COPD cohort study performed as previously described.[@b8-copd-10-1075],[@b10-copd-10-1075] In summary, subjects were aged 40 or over and had a physician diagnosis of COPD and a postbronchodilator forced expiratory volume in 1 second (FEV~1~)/forced vital capacity (FVC) of less than 0.7. All subjects had experienced at least one exacerbation requiring emergency health care utilization in the 12 months prior to recruitment. Subjects were seen for four visits when stable, at 3-monthly intervals, for the study duration. A "stable" visit was defined as one where subjects were free from an exacerbation episode (identified according to health care utilization and daily diary cards) for at least 6 weeks prior to the visit. Subjects with a clinical diagnosis of asthma or on prophylactic antibiotic therapy were excluded. All subjects gave written informed consent, and the study was approved by the Regional Ethics Committee of Leicestershire, Northamptonshire, and Rutland (reference number: 07/H0406/157).

Measurements
------------

At each visit, spirometry was performed according to guidelines.[@b11-copd-10-1075] Health-related quality of life and symptom assessments were measured using a visual analog scale (VAS)[@b12-copd-10-1075] for the domains of dyspnea, cough, sputum production, and sputum purulence; the Chronic Respiratory Disease Questionnaire (CRQ),[@b13-copd-10-1075] and the St George's Respiratory Questionnaire (SGRQ).[@b14-copd-10-1075] Venous blood was obtained for measurement of a full blood count and C-reactive protein (CRP). Spontaneous or induced sputum was collected and processed for differential cell counts and detection of bacteria. Identification of PPMs in sputum culture (*H. influenzae, M. catarrhalis, Streptococcus pneumoniae, Staphylococcus aureus*, and *Pseudomonas aeruginosa*) was performed according to the Health Protection Agency (HPA) standard operating procedures.[@b15-copd-10-1075] Sputum culture that did not show a dominant pathogenic respiratory pathogen was classified as having nonsignificant growth (NSG). Total aerobic counts were obtained by first plating homogenized sputum, serially diluted in Dulbecco's phosphate-buffered saline, on chocolate and blood agar plates, and then, counting the number of colonies (colony-forming units \[CFUs\]) as previously described.[@b16-copd-10-1075] qPCR was used to estimate bacterial load based on the abundance of 16S ribosomal subunit, variable region V4, and V5 encoding genes, and genome copy numbers of *H. influenzae, M. catarrhalis, S. pneumoniae*, and *S. aureus*, as described previously.[@b8-copd-10-1075] In brief, total bacterial DNA was extracted from 500 μL of homogenized sputum using the QIAmp DNA Mini Kit (QIAGEN Ltd, Venlo, the Netherlands). DNA standards for qPCR were prepared from pure DNA cultures of *Escherichia coli, H. influenzae, M. catarrhalis, S. pneumoniae*, and *S. aureus*. The SYBR^®^ green assay (Applied Biosystems^®^; Life Technologies Corp, Carlsbad, CA, USA) was used to quantify qPCR total bacterial load (16S) and qPCR pathogen-specific *H. influenzae* and *S. aureus* bacterial load. The TaqMan^®^ assay (Applied Biosystems; Life Technologies Corp) was used for quantification of qPCR pathogen-specific *M. catarrhalis* and *S. pneumonia* bacterial loads. The lower detection limit of a CFU was ≥1×10^5^/mL of sputum, and a threshold of ≥1×10^6^ genome copies/mL was regarded as clinically significant. Neutrophilic airway inflammation was defined as a sputum neutrophil count \>60%.[@b17-copd-10-1075]

Statistical analysis
--------------------

Statistical analysis was performed using PASW Statistics for Windows, Version 18.0 (SPSS Inc. Chicago, IL, USA) and GraphPad Prism version 6 (GraphPad Software Inc., La Jolla, CA, USA). Normality tests were performed using the Kolmogorov--Smirnov test. Parametric and nonparametric data were presented as mean (standard deviation \[SD\]) and median (interquartile range). Log-transformed data were expressed as geometric mean (95% confidence interval \[CI\]). Repeatability was assessed using intraclass correlation coefficients (ICCs) and a one-way random effects average measures model. Association was measured using Pearson and Spearman rank correlation coefficients. One-way analysis of variance, Kruskal--Wallis, and chi-square tests were used to compare clinical characteristics across groups. *P*-values of \<0.05 were considered to be statistically significant.

Results
=======

At study entry, 174 subjects provided an adequate sputum sample for any quantification. The most common pathogen detected was *H. influenzae*, occurring in 52/152 (34%) of qPCR samples and 29/174 (17%) of culture samples. *M. catarrhalis, S. pneumoniae*, and *S. aureus* occurred in 24 (16%), 19 (13%), and seven (5%) of the qPCR pathogen-specific samples and in six (8%), four (2%), and three (2%) of all cultures, respectively. *P*. *aeruginosa* was detected in eight (5%) culture samples and was not quantified by qPCR. There was 98% concordance between the corresponding PPM on routine culture and the qPCR pathogen-specific pathogen; all but one culture (*S. pneumoniae* culture) ([Figure 1](#f1-copd-10-1075){ref-type="fig"}) had a qPCR pathogen-specific bacterial load \>10^6^ copies/mL. In PPM-positive culture samples compared with NSG culture, there was a 4.6-fold increase in CFUs (95% CI of fold difference, 2.0 to 10.5; *P*\<0.001) and a 4.1-fold increase in total qPCR 16S bacterial load (95% CI of fold difference, 1.9 to 8.8; *P*\<0.001). Subjects that were positive for PPM at culture or qPCR had more severe airflow limitation, increased symptoms, and increased inflammatory indices ([Table 1](#t1-copd-10-1075){ref-type="table"}).

The mean sputum neutrophil count in patients with positive pathogen-specific qPCR (ie, bacterial loads above and below 10^6^ copies/mL) was 75% compared with 64% in those with negative pathogen-specific qPCR (mean difference 12%, 95% CI, 5% to 18%; *P*\<0.001). There were no differences in age, smoking pack-years, FEV~1~, or FEV~1~% predicted, in subjects that were culture-negative and qPCR-positive compared with the remainder of the group. Pathogen-specific qPCR identified subjects with neutrophilic airway inflammation, whether associated with a positive culture or not ([Figure 1](#f1-copd-10-1075){ref-type="fig"}). Only qPCR pathogen-specific *H. influenzae* bacterial load correlated with percentage sputum neutrophils and sputum total cell count (*r*=0.37, *P*\<0.001 and *r*=0.26, *P*=0.017, respectively). A dose-response sputum neutrophil relationship was seen with *H. influenzae* only ([Table 2](#t2-copd-10-1075){ref-type="table"}). The sensitivity and specificity of qPCR to detect neutrophilic inflammation was 75% and 34% in comparison with that of the standard culture technique, which was 37% and 87%, respectively.

In 65 subjects, sputum was available at every time point over 1 year (four visits). Repeatability of pathogen identification in these subjects, analyzed by the ICC (95% CI), for CFU and total 16S was 0.80 (0.68 to 0.88) and 0.61 (0.37 to 0.77), respectively. The mean within-subject log SD for CFU and 16S was 0.62 and 0.76, respectively. Repeatability was greatest for *H. influenzae* pathogen-specific qPCR ([Table 3](#t3-copd-10-1075){ref-type="table"}). Persistence of pathogen, defined as the occurrence of three or more samples positive for the same pathogen, was only observed in *H. influenzae* culture (n=8) and pathogen-specific *H. influenzae* qPCR (n=19). Persistence of *H. influenzae*, whether defined by culture, qPCR detection, or both, was associated with lower FEV~1~, increased neutrophilic airway inflammation, and worse symptoms, both at baseline and over time ([Table 4A](#t4-copd-10-1075){ref-type="table"} and B).

Discussion
==========

Our findings indicate that sputum qPCR is a sensitive measure of airway bacterial presence in patients with stable COPD and identifies patients with neutrophilic inflammation. Bacteria qPCR copy numbers were repeatable within subjects and were particularly important in detecting a group of patients with persistent bacterial presence, severe neutrophilic airway inflammation, and poor clinical outcomes. qPCR has the additional advantages of providing a rapid and quantifiable result. Collectively, these properties suggest important advantages over conventional culture-based methods for the assessment of airway bacteria in patients with airway disease.

*H. influenzae* was the most prevalent airway pathogen detected by qPCR and the only pathogen to be identified persistently in patients with stable COPD, in keeping with earlier, culture-based studies in patients with stable COPD.[@b1-copd-10-1075],[@b2-copd-10-1075] Our study extends these earlier studies by showing that bacterial presence, whether assessed by qPCR, culture, or both, is associated with increased neutrophilic airway inflammation and, when persistent, with worse clinical outcomes measured by the SGRQ, with clinical but not statistically significant deterioration. Furthermore, our study is consistent with a more recent study investigating qPCR pathogen detection in patients with COPD,[@b18-copd-10-1075] although we extended this finding to assess airway inflammation and outcomes longitudinally. A noninterventional study such as this cannot establish a causal link between the presence of bacteria and increased neutrophilic airway, but such a relationship is likely, as short-term antibiotic treatment reduces both bacterial load and the sputum neutrophil count in patients with stable COPD.[@b9-copd-10-1075],[@b19-copd-10-1075] We cannot exclude the possibility that the relationships seen are a function of the presence of *H. influenzae* alone. The dose-response relationship between *H. influenzae* and the sputum neutrophil count identified by qPCR, and the demonstration that persistent presence of *H. influenzae* is associated with particularly high sputum neutrophil counts, would be consistent with this. A causal link with this pathogen and neutrophilic airway inflammation is also biologically plausible since patients with COPD have been shown to have impaired innate immune response and a reduced phagocytic response to *H. influenza*.[@b20-copd-10-1075] Moreover, nontypeable *H. influenzae*, in contrast to other respiratory PPMs, has been found to have the ability to invade lung parenchyma and can be identified intracellularly.[@b21-copd-10-1075],[@b22-copd-10-1075] Once established in the airway, *H. influenzae* might directly drive neutrophilic airway inflammation since it increases airway mucosal TNF production and has a marked cytotoxic T cell response;[@b23-copd-10-1075] we recently observed that *H. influenzae* presence is an independent predictor of airway production of TNF and IL1.[@b24-copd-10-1075]

The most noteworthy and important finding of our study is that a significant number of sputum samples were culture-negative but contained high copy numbers for a PPM, using qPCR. This pattern of pathogen-specific PPM isolation was particularly seen with *H. influenzae*; it was associated with increased neutrophilic airway inflammation and, when present repeatedly, with worse lung function and quality of life. One potential explanation is that nonviable pathogens contribute to neutrophilic airway inflammation, as has been shown for *H. Influenzae* in animal models.[@b25-copd-10-1075] Alternatively, pathogens might exist in a quiescent state, contributing to airway inflammation and only detectable using molecular methods. An earlier longitudinal study repeatedly assessing airway bacteria by culture methods strongly supports such behavior for *H. influenza*.[@b26-copd-10-1075] Gaps in *H. influenzae* detection by sputum culture over 1 to 6 months were invariably associated with molecular evidence of persistence of the same strain of *H. influenza*.[@b26-copd-10-1075] Long-term treatment with prophylactic antibiotics, in particular low-dose macrolides, is associated with a reduction in symptoms and exacerbation frequency in subjects with COPD,[@b27-copd-10-1075],[@b28-copd-10-1075] an effect specific to subjects with chronic bronchitis and purulent sputum.[@b29-copd-10-1075] Although it remains to be established whether this effect is mediated by a reduction in airway bacteria, repeated small, randomized, placebo-controlled trials have shown parallel reductions in bacterial numbers and neutrophilic airway inflammation during antibiotic treatment.[@b19-copd-10-1075],[@b28-copd-10-1075] Future stud ies should investigate whether the response to long-term low-dose macrolides is associated with traditional and molecular measures of airway bacteria. Targeting therapy to a particularly responsive population would be an advance, as long-term macrolide therapy has been associated with hearing decrements and an increased rate of macrolide-resistant infections, including nontuberculous mycobacteria infection.[@b27-copd-10-1075]

A limitation of our study includes our failure to use molecular techniques to identify *P. aeruginosa*, or to investigate variation between the sampling position and site and the absence of information on change in bacterial strain. Further studies to evaluate these potentially important aspects are thus required. We have also been unable to assess the functional properties of neutrophils in these subjects, to determine whether there is differential expression, migration, or function. However, recent experimental assays have revealed that neutrophil phagocytosis of bacteria is similar between healthy controls and subjects with COPD,[@b30-copd-10-1075] although this has yet to be studied in airway neutrophils. A final limitation is that computed tomography was not undertaken as part of the study protocol, so we are not in a position to determine whether the presence of bronchiectasis was an important cofactor in these subjects. We have previously shown that in a subgroup of this cohort, emphysema is the most common radiological finding, and airway inflammation is similar in patients with emphysema or bronchiectasis,[@b31-copd-10-1075] suggesting that the presence of bronchiectasis alone is unlikely to be an important factor. We were unable to show any differences in exacerbation frequency in the population with higher bacterial burden as measured by qPCR or culture. Potentially, this may reflect selection bias, as subjects were selected on the basis of a prior history of exacerbations. Exacerbations are recognized to be heterogeneous in mechanism and pathogenesis,[@b32-copd-10-1075] and another possibility is that bacterial presence is associated with an increased rate of a particular type of event.

To conclude, we have shown that a significant number of patients with stable COPD have evidence of airway PPMs, that qPCR is a more sensitive measure of this than is traditional culture, and that patients with a bacteria-associated disease have increased neutrophilic airway inflammation. The presence of a positive correlation between qPCR copy numbers and the sputum neutrophil count, and the finding that patients with persistently positive sputum samples have particularly severe neutrophilic airway inflammation and poor clinical outcomes, would be consistent with a causal link. *H. influenzae* was the most commonly isolated pathogen, the only one to be identified repeatedly, and was most closely associated with neutrophilic airway inflammation and poor clinical outcomes, suggesting a more important role for this pathogen in stable COPD. Further work is warranted to investigate whether subjects with this pattern of disease benefit most from prophylactic antimicrobial therapy and to further define the role of *H. influenzae* in the pathogenesis of COPD.
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![Scatter correlation plot of sputum neutrophils (x-axis) with pathogen-specific bacterial load (y-axis) for samples above the limit of detection (qPCR LLD \>1×10^4^ copies/mL of sputum).\
**Notes:** Data were categorized into respective sputum culture pathogens (NSG, HI, MC, SP, and SA). (**A**) HI. (**B**) MC. (**C**) SP. (**D**) SA pathogen-specific qPCR. The horizontal dashed line on the y-axis related to pathogen-specific qPCR bacterial load of 10^6^. The vertical dashed line on the x-axis related to sputum neutrophil count at 60% (neutrophilic airway inflammation).\
**Abbreviations:** NSG, nonsignificant growth; HI, *Haemophilus influenzae*; LLD, lower limit of detection; MC, *Moraxella catarrhalis*; qPCR, quantitative real-time polymerase chain reaction; SP, *Streptococcus pneumoniae*; SA, *Staphylococcus aureus*.](copd-10-1075Fig1){#f1-copd-10-1075}

###### 

Baseline clinical and bacterial characteristics of subjects with and without PPM, on routine culture and by qPCR

                                                                                                                                         Routine culture     qPCR PPM detection                                                               
  -------------------------------------------------------------------------------------------------------------------------------------- ------------------- ------------------------------------------------------------ ------------------- ------------------------------------------------------------
  Males, n (%)                                                                                                                           88 (71)             35 (70)                                                      27 (61)             59 (77)
  Age, years                                                                                                                             68 (9)              69 (8)                                                       70 (8)              67 (9)
  Pack-years smoked, mean (range)                                                                                                        52 (10--159)        54 (10--153)                                                 53 (10--159)        54 (10--156)
  FEV~1~ (L)[\#](#tfn2-copd-10-1075){ref-type="table-fn"}                                                                                1.38 (0.54)         1.18 (0.53)[¥](#tfn7-copd-10-1075){ref-type="table-fn"}      1.29 (0.48)         1.29 (0.55)
  FEV~1~ (% predicted)[\#](#tfn2-copd-10-1075){ref-type="table-fn"}                                                                      52 (20)             46 (18)[¥](#tfn7-copd-10-1075){ref-type="table-fn"}          52 (18)             48 (19)
  FEV~1~/FVC ratio (%)[\#](#tfn2-copd-10-1075){ref-type="table-fn"}                                                                      52 (12)             46 (13)[¥](#tfn7-copd-10-1075){ref-type="table-fn"}          51 (12)             47 (13)[ᴥ](#tfn8-copd-10-1075){ref-type="table-fn"}
  Exacerbations frequency/yr                                                                                                             3.5 (2.7)           4.1 (2.7)                                                    3.5 (2.7)           3.6 (2.6)
  Inhaled corticosteroid dose, μg                                                                                                        1,279 (748)         1,675 (749)[¥](#tfn7-copd-10-1075){ref-type="table-fn"}      1,416 (651)         1,493 (768)
  SGRQ, units                                                                                                                            52.3 (17.5)         54.6 (16.9)                                                  50.5 (13.7)         53.0 (19.4)
  CRQ, units                                                                                                                             4.1 (1.1)           4.0 (1.2)                                                    4.8 (1.3)           4.0 (1.2)
  VAS cough, mm                                                                                                                          36 (26)             46 (27)[¥](#tfn7-copd-10-1075){ref-type="table-fn"}          37 (27)             41 (26)
  VAS dyspnea, mm                                                                                                                        49 (26)             51 (26)                                                      53 (27)             48 (26)
  VAS sputum production, mm                                                                                                              35 (26)             49 (26)[¥](#tfn7-copd-10-1075){ref-type="table-fn"}          31 (26)             44 (26)[ᴥ](#tfn8-copd-10-1075){ref-type="table-fn"}
  VAS sputum purulence, mm                                                                                                               31 (25)             39 (27)                                                      33 (26)             28 (27)
  Peripheral leukocyte count, ×10^9^ cells/mL[\*](#tfn3-copd-10-1075){ref-type="table-fn"}                                               8.2 (7.8--8.5)      8.9 (8.2--9.7)[¥](#tfn7-copd-10-1075){ref-type="table-fn"}   8.7 (8.1--9.5)      8.4 (7.9--8.9)
  Peripheral neutrophil count, ×10^9^ cells/mL[\*](#tfn3-copd-10-1075){ref-type="table-fn"}                                              5.2 (4.9--5.5)      5.8 (5.3--6.5)[¥](#tfn7-copd-10-1075){ref-type="table-fn"}   5.7 (5.1--6.3)      7.3 (4.9--5.8)
  Peripheral eosinophil count, ×10^9^ cells/mL[\*](#tfn3-copd-10-1075){ref-type="table-fn"}                                              0.21 (0.18--0.24)   0.21 (0.18--0.25)                                            0.22 (0.18--0.28)   0.22 (0.19--0.25)
  C-reactive protein, mg/L[†](#tfn4-copd-10-1075){ref-type="table-fn"}                                                                   3 (3--11)           6 (3--18)                                                    3 (3--12)           6 (3--14)
  Total cell count, ×10^6^ cells/g sputum[\*](#tfn3-copd-10-1075){ref-type="table-fn"}                                                   2.5 (2.0--3.1)      6.0 (4.2--8.5)[¥](#tfn7-copd-10-1075){ref-type="table-fn"}   2.7 (1.9--4.1)      4.1 (3.1--5.5)[ᴥ](#tfn8-copd-10-1075){ref-type="table-fn"}
  Sputum neutrophil differential, %                                                                                                      64 (22)             81 (19)[¥](#tfn7-copd-10-1075){ref-type="table-fn"}          65 (18)             75 (22)[ᴥ](#tfn8-copd-10-1075){ref-type="table-fn"}
  Sputum eosinophil differential, %[\*](#tfn3-copd-10-1075){ref-type="table-fn"}                                                         1.4 (1.1--1.8)      0.9 (0.6--1.2)[¥](#tfn7-copd-10-1075){ref-type="table-fn"}   1.6 (1.0--2.6)      1.2 (0.8--1.6)
  Proportion with neutrophilic inflammation                                                                                              62%                 86%[¥](#tfn7-copd-10-1075){ref-type="table-fn"}              63%                 79%[ᴥ](#tfn8-copd-10-1075){ref-type="table-fn"}
  Log colony forming units/mL of sputum[˫](#tfn5-copd-10-1075){ref-type="table-fn"}                                                      6.9 (6.7--7.1)      7.6 (7.2--7.9)[¥](#tfn7-copd-10-1075){ref-type="table-fn"}   6.8 (6.5--7.1)      7.3 (7.0--7.6)[ᴥ](#tfn8-copd-10-1075){ref-type="table-fn"}
  Total 16S log genome copies/mL of sputum[ⱶ](#tfn5-copd-10-1075){ref-type="table-fn"},[\*\*](#tfn6-copd-10-1075){ref-type="table-fn"}   8.3 (8.1--8.4)      8.9 (7.2--9.2)[¥](#tfn7-copd-10-1075){ref-type="table-fn"}   8.1 (7.8--8.3)      8.8 (8.6--9.0)[ᴥ](#tfn8-copd-10-1075){ref-type="table-fn"}
  Proportion HI qPCR codetection                                                                                                         47%                 70%[¥](#tfn7-copd-10-1075){ref-type="table-fn"}              0%                  82%[ᴥ](#tfn8-copd-10-1075){ref-type="table-fn"}
  Proportion MC qPCR codetection                                                                                                         28%                 54%[¥](#tfn7-copd-10-1075){ref-type="table-fn"}              0%                  51%[ᴥ](#tfn8-copd-10-1075){ref-type="table-fn"}
  Proportion SP qPCR codetection                                                                                                         18%                 39%[¥](#tfn7-copd-10-1075){ref-type="table-fn"}              0%                  28%[ᴥ](#tfn8-copd-10-1075){ref-type="table-fn"}
  Proportion SA qPCR codetection                                                                                                         9%                  10%                                                          0%                  14%[ᴥ](#tfn8-copd-10-1075){ref-type="table-fn"}
  HI log genome copies/mL qPCR[ⱶ](#tfn5-copd-10-1075){ref-type="table-fn"},[\*\*](#tfn6-copd-10-1075){ref-type="table-fn"}               4.3 (3.9--4.6)      6.5 (5.7--7.3)[¥](#tfn7-copd-10-1075){ref-type="table-fn"}   2.8 (2.7--2.8)      6.4 (5.9--6.9)[ᴥ](#tfn8-copd-10-1075){ref-type="table-fn"}
  MC log genome copies/mL qPCR[ⱶ](#tfn5-copd-10-1075){ref-type="table-fn"},[\*\*](#tfn6-copd-10-1075){ref-type="table-fn"}               3.5 (3.3--3.8)      5.4 (4.6--6.3)[¥](#tfn7-copd-10-1075){ref-type="table-fn"}   2.7 (2.7--2.7)      5.0 (4.4--5.5)[ᴥ](#tfn8-copd-10-1075){ref-type="table-fn"}
  SP log genome copies/mL qPCR[ⱶ](#tfn5-copd-10-1075){ref-type="table-fn"},[\*\*](#tfn6-copd-10-1075){ref-type="table-fn"}               3.5 (3.2--3.7)      4.0 (3.4--4.5)                                               2.7 (2.7--2.7)      4.2 (3.8--4.7)[ᴥ](#tfn8-copd-10-1075){ref-type="table-fn"}
  SA log genome copies/mL qPCR[ⱶ](#tfn5-copd-10-1075){ref-type="table-fn"},[\*\*](#tfn6-copd-10-1075){ref-type="table-fn"}               3.0 (2.8--3.2)      3.1 (2.7--3.6)                                               2.7 (2.7--2.7)      3.3 (2.9--3.6)[ᴥ](#tfn8-copd-10-1075){ref-type="table-fn"}

**Notes:** Data were presented as mean (standard deviation) unless stated.

Postbronchodilator.

Geometric mean (95% confidence interval).

Median (interquartile range).

Mean (95% confidence interval).

Based on 16S qPCR log genome copies/mL.

*P*\<0.05 between −PPM and +PPM culture groups (Student's *t*-test, Mann--Whitney, or chi-square, as appropriate).

*P*\<0.05 between −PPM and +PPM qPCR groups, \>10^6^ copies/mL (Student's *t*-test, Mann--Whitney, or chi-square, as appropriate). Neutrophilic airway inflammation was defined as greater than 60% sputum neutrophils.

**Abbreviations:** CRQ, Chronic Respiratory Disease Questionnaire; FEV~1~, forced expiratory volume in 1 second; FVC, forced vital capacity; HI, *Haemophilus influenzae*; MC, *Moraxella catarrhalis*; PPM, potentially pathogenic microorganism; −PPM, PPM-negative; +PPM, PPM-positive; qPCR, quantitative real-time polymerase chain reaction; SA, *Staphylococcus aureus*; SGRQ, St George's Respiratory Questionnaire; SP, *Streptococcus pneumoniae*; VAS, visual analog scale.

###### 

Clinical and inflammatory characteristics of COPD patients with positive qPCR categorized into absent (\<10^6^), present (between 10^6^ to 10^7^), and highly present (greater than 10^8^ copies/mL)

                                                                                 *Haemophilus influenzae*   *Moraxella catarrhalis*   *Streptococcus pneumoniae*                                                                                                                            
  ------------------------------------------------------------------------------ -------------------------- ------------------------- ---------------------------- -------- ---------------- ----------------- ----------------- ------ ---------------- ---------------- ----------------- ------
  n                                                                              30                         30                        22                                    6                2                 5                        6                3                2                 
  Any +PPM sputum culture                                                        13%                        23%                       91%                          \<0.01   17%              50%               60%               0.38   67%              0%               50%               0.20
  Log CFU/mL[\*](#tfn11-copd-10-1075){ref-type="table-fn"}                       7.0 (6.6--7.4)             7.1 (6.7--7.4)            7.7 (7.2--8.3)               0.04     7.0 (5.1--8.8)   7.8 (7.7--8.0)    8.7 (6.8--10.6)   0.19   7.2 (6.6--7.8)   6.6 (4.1--9.1)   5.5 (5.3--5.6)    0.05
  Log total 16S genome copies/mL[\*](#tfn11-copd-10-1075){ref-type="table-fn"}   8.1 (7.7--8.4)             8.5 (8.2--8.8)            9.2 (8.8--9.6)               \<0.01   8.1 (6.8--9.4)   9.4 (5.6--13.2)   9.7 (8.9--10.4)   0.06   9.3 (8.8--9.7)   8.4 (7.7--9.0)   8.4 (5.5--11.4)   0.01
  Sputum neutrophils, %                                                          66 (22)                    72 (21)                   84 (16)                      0.01     65 (25)          72 (25)           74 (25)           0.86   66 (30)          69 (30)          33 (28)           0.45
  CRQ dyspnea, units                                                             3.5 (1.3)                  2.7 (0.9)                 3.1 (1.2)                    0.04     3.6 (0.8)        2.7 (0.7)         4.0 (0.9)         0.23   3.7 (1.2)        2.7 (0.6)        2.7 (0.4)         0.33
  CRQ fatigue, units                                                             3.8 (1.3)                  3.2 (1.1)                 3.8 (1.2)                    0.13     4.1 (1.2)        3.4 (0.9)         4.5 (0.7)         0.45   4.3 (1.3)        4.4 (1.1)        3.4 (2.3)         0.70
  CRQ emotion, units                                                             4.5 (1.3)                  4.2 (1.3)                 4.6 (1.5)                    0.58     4.3 (1.4)        3.9 (1.3)         5.5 (0.9)         0.24   5.1 (1.4)        5.6 (0.1)        4.1 (1.3)         0.39
  CRQ mastery, units                                                             4.9 (1.5)                  4.5 (1.6)                 4.7 (1.5)                    0.61     4.2 (1.5)        3.6 (1.2)         5.3 (0.9)         0.24   5.9 (0.8)        6.2 (1.0)        3.5 (2.1)         0.06
  VAS cough, mm                                                                  37 (25)                    39 (27)                   39 (25)                      0.94     30 (27)          57 (14)           49 (24)           0.34   33 (13)          42 (38)          44 (42)           0.83
  VAS dyspnea, mm                                                                47 (25)                    45 (26)                   51 (25)                      0.65     43 (31)          76 (13)           39 (25)           0.29   44 (19)          61 (29)          37 (20)           0.36
  VAS sputum purulence, mm                                                       39 (24)                    40 (26)                   48 (26)                      0.51     20 (25)          68 (28)           42 (26)           0.69   28 (12)          59 (41)          41 (35)           0.90
  VAS sputum volume, mm                                                          33 (26)                    35 (26)                   42 (32)                      0.40     18 (22)          26 (16)           27 (14)           0.11   37 (20)          53 (18)          31 (2)            0.22

**Notes:** Data for *Staphylococcus aureus* not analyzed or presented here. Data are presented as mean (SD) unless stated.

Mean (95% CI).

**Abbreviations:** CFU, colony-forming unit; CRQ, Chronic Respiratory Disease Questionnaire; +PPM, potentially pathogenic microorganism-positive; qPCR, quantitative real-time polymerase chain reaction; VAS, visual analog scale.

###### 

Frequency of sputum PPM detection in culture or qPCR, in 65 COPD subjects with repeated sampling over 12 months

  Number of times PPM detected   0, n (%)     1, n (%)     2, n (%)     3/4, n (%)   Repeatability index   Mean within-subject log SD
  ------------------------------ ------------ ------------ ------------ ------------ --------------------- ----------------------------
  +PPM culture                   30 (46.2%)   16 (24.6%)   10 (15.4%)   9 (13.8%)    0.74                  NA
  HI culture                     35 (54.8%)   16 (24.6%)   6 (9.2%)     8 (12.3%)    0.51                  NA
  MC culture                     59 (90.8%)   4 (6.2%)     2 (3.0%)     0 (0.0%)     0.37                  NA
  SP culture                     57 (87.7%)   3 (4.6%)     5 (7.8%)     0 (0.0%)     0.49                  NA
  SA culture                     64 (98%)     1 (1.5%)     0 (0.0%)     0 (0.0%)     0.00                  NA
  CFU                            NA           NA           NA           65 (100%)    0.80                  0.62
  Total 16S                      NA           NA           NA           65 (100%)    0.61                  0.76
  HI qPCR                        7 (11%)      10 (15%)     16 (25%)     32 (49%)     0.84                  1.39
  MC qPCR                        14 (22%)     19 (29%)     13 (20%)     19 (29%)     0.75                  1.46
  P qPCR                         23 (35%)     15 (23%)     15 (23%)     12 (18%)     0.62                  1.26
  SA qPCR                        49 (75%)     11 (17%)     2 (3%)       3 (5%)       0.14                  0.36

**Notes:** The qPCR detection threshold was \>10^6^ genome copies/mL of sputum. The repeatability index was a measure of the repeatability of a positive detection of pathogen.

**Abbreviations:** CFU, colony-forming unit; HI, *Haemophilus influenzae*; MC, *Moraxella catarrhalis*; NA, not applicable; PPM, potentially pathogenic microorganism; +PPM, PPM-positive; qPCR, quantitative real-time polymerase chain reaction; SA, *Staphylococcus aureus*; SD, standard deviation; SP, *Streptococcus pneumoniae*.

###### 

Clinical and inflammatory baseline characteristics in COPD subjects, with sputum sampling over 12 months

  Categorized according to qPCR threshold above 10^6^ for HI-detection subgroups                                                                                
  ----------------------------------------------------------------------------------- ------------------------ ------------------------ ----------------------- -------
  Exacerbations/yr during study[\*](#tfn16-copd-10-1075){ref-type="table-fn"}         2.6 (1.7)                2.6 (1.5)                2.5 (1.2)               0.975
  Proportion of frequent exacerbations[‡](#tfn18-copd-10-1075){ref-type="table-fn"}   36%                      38%                      53%                     0.514
  Sputum total cell count, ×10^6^/g[¥](#tfn17-copd-10-1075){ref-type="table-fn"}      3.1 (1.7--5.4)           2.4 (1.4--3.9)           6.9 (3.7--12.8)         0.026
  Sputum neutrophils (%)[\*](#tfn16-copd-10-1075){ref-type="table-fn"}                67 (21)                  64 (22)                  79 (22)                 0.070
  Total sputum neutrophils, ×10^6^/g[¥](#tfn17-copd-10-1075){ref-type="table-fn"}     2.1 (1.1--3.9)           1.5 (0.8--2.7)           5.2 (2.4--11.2)         0.023
  Δ sputum neutrophils                                                                −2.4 (−9.9 to 5.1)       −12.2 (−22.7 to −1.7)    0.6 (−11.6 to 12.7)     0.160
  Δ FEV~1~ (L)[\#](#tfn19-copd-10-1075){ref-type="table-fn"}                          −0.06 (−1.5 to 0.04)     −0.12 (−0.21 to −0.03)   −0.03 (−0.13 to 0.08)   0.437
  Δ FVC[\#](#tfn19-copd-10-1075){ref-type="table-fn"}                                 −0.25 (−0.45 to −0.05)   −0.40 (−0.58 to −0.23)   −0.00 (−0.25 to 0.25)   0.029
  Δ VAS cough (mm)                                                                    2 (−6 to 9)              −2 (−17 to 13)           3 (−9 to 15)            0.809
  Δ VAS dyspnea (mm)                                                                  −2 (−15 to 11)           23 (9 to 36)             2 (−10 to 14)           0.016
  Δ VAS production (mm)                                                               6 (−4 to 15)             −4 (−16 to 8)            −10 (−23 to 3)          0.122
  Δ VAS purulence (mm)                                                                12 (3 to 21)             0 (−14 to 15)            2 (−13 to 17)           0.307
  Δ SGRQ symptoms                                                                     −5.02 (−13.15 to 3.11)   3.15 (−7.30 to 13.61)    6.39 (−0.90 to 13.7)    0.134
  Δ SGRQ activity                                                                     1.63 (−5.00 to 8.26)     5.63 (−3.87 to 15.13)    6.09 (0.18 to 12.0)     0.599
  Δ SGRQ impacts                                                                      −4.13 (−9.95 to 1.68)    2.53 (−7.04 to 12.11)    0.90 (−3.48 to 5.28)    0.288
  Δ SGRQ total                                                                        −2.60 (−7.70 to 2.49)    5.95 (−1.00 to 12.89)    3.22 (−1.09 to 7.54)    0.060

  Categorized according to detection of any HI PPM on standard culture subgroups                                                                                
  ----------------------------------------------------------------------------------- ------------------------ ------------------------ ----------------------- -------
  Exacerbations/yr during study[\*](#tfn16-copd-10-1075){ref-type="table-fn"}         2.5 (1.6)                2.6 (1.5)                2.5 (1.1)               0.997
  Proportion of frequent exacerbations[‡](#tfn18-copd-10-1075){ref-type="table-fn"}   34%                      45%                      63%                     0.310
  Sputum total cell count, ×10^6^/g[¥](#tfn17-copd-10-1075){ref-type="table-fn"}      2.6 (1.6--4.1)           4.4 (2.6--7.6)           8.8 (3.2--24.1)         0.037
  Sputum neutrophils (%)[\*](#tfn16-copd-10-1075){ref-type="table-fn"}                66 (21)                  71 (25)                  81 (20)                 0.262
  Total sputum neutrophils, ×10^6^/g[¥](#tfn17-copd-10-1075){ref-type="table-fn"}     1.7 (1.0--2.9)           2.9 (1.5--5.7)           6.9 (2.1--22.7)         0.058
  Δ sputum neutrophils                                                                −2.0 (−8.4 to 4.3)       −12.3 (−22.9 to −1.73)   8.0 (−13.9 to 30.0)     0.055
  Δ FEV~1~ (L)[\#](#tfn19-copd-10-1075){ref-type="table-fn"}                          −0.10 (−0.18 to −0.02)   −0.07 (−0.15 to 0.01)    0.12 (−0.11 to 0.35)    0.071
  Δ FVC[\#](#tfn19-copd-10-1075){ref-type="table-fn"}                                 −0.31 (−0.47 to −0.15)   −0.20 (−0.41 to 0.02)    0.06 (−0.32 to 0.44)    0.132
  Δ VAS cough (mm)                                                                    2 (−7 to 11)             4 (−8 to 15)             −9 (−26 to 9)           0.484
  Δ VAS dyspnea (mm)                                                                  6 (−5 to 17)             15 (1 to 29)             −6 (−27 to 15)          0.242
  Δ VAS production (mm)                                                               6 (−3 to 14)             −10 (−21 to 2)           −16 (−32 to 0)          0.024
  Δ VAS purulence (mm)                                                                8 (−1 to 17)             5 (−9 to 19)             −4 (−22 to 15)          0.552
  Δ SGRQ symptoms                                                                     −1.26 (−7.84 to 5.31)    1.11 (−8.33 to 10.56)    8.15 (−7.81 to 24.11)   0.476
  Δ SGRQ activity                                                                     −0.51 (−5.94 to 4.92)    9.94 (2.25 to 17.64)     7.15 (−1.86 to 16.16)   0.050
  Δ SGRQ impacts                                                                      −3.38 (−8.48 to 1.73)    2.13 (−5.19 to 9.46)     1.91 (−3.60 to 7.43)    0.337
  Δ SGRQ total                                                                        −1.28 (−5.50 to 2.95)    4.21 (−2.09 to 10.51)    4.35 (−1.29 to 10.00)   0.213

**Notes:** N=65. Data were presented as mean difference (95% confidence interval) unless stated.

Mean (SD),

Geometric mean (95% confidence interval).

Frequent exacerbations was defined as the occurrence of three or more exacerbations during 12 months of study.

Postbronchodilator.

ANOVA or chi-square, as appropriate. Δ represents change from baseline over 12 months of study.

**Abbreviations:** −/−, never detected; +/−, sometimes detected; +/+, always detected +/+; ANOVA, analysis of variance; FEV~1~, forced expiratory volume in 1 second; FVC, forced vital capacity; HI, *Haemophilus influenzae*; PPM, potentially pathogenic microorganisms; qPCR, quantitative real-time polymerase chain reaction; SD, standard deviation; SGRQ, St George's Respiratory Questionnaire; VAS, visual analog scale.
